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A B S T R A C T
Background
Pressure ulcers, which are localised injury to the skin, or underlying tissue or both, occur when people are unable to reposition themselves
to relieve pressure on bony prominences. Pressure ulcers are often difficult to heal, painful and impact negatively on the individual’s
quality of life. The cost implications of pressure ulcer treatment are considerable, compounding the challenges in providing cost
effective, efficient health services. Efforts to prevent the development of pressure ulcers have focused on nutritional support, pressure
redistributing devices, turning regimes and the application of various topical agents and dressings designed to maintain healthy skin,
relieve pressure and prevent shearing forces. Although products aimed at preventing pressure ulcers are widely used, it remains unclear
which, if any, of these approaches are effective in preventing the development of pressure ulcers.
Objectives
To evaluate the effects of dressings and topical agents on the prevention of pressure ulcers, in people of any age without existing pressure
ulcers, but considered to be at risk of developing a pressure ulcer, in any healthcare setting.
Search methods
In February 2013 we searched the following electronic databases to identify reports of relevant randomised clinical trials (RCTs):
the Cochrane Wounds Group Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane
Library); Database of Abstracts of Reviews of Effects (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other
Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL.
Selection criteria
We included RCTs evaluating the use of dressings, topical agents, or topical agents with dressings, compared with a different dressing,
topical agent, or combined topical agent and dressing, or no intervention or standard care, with the aim of preventing the development
of a pressure ulcer.
Data collection and analysis
We assessed trials for their appropriateness for inclusion and for their risk of bias. This was done by two review authors working
independently, using pre-determined inclusion and quality criteria.
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Main results
Five trials (940 participants) of unclear or high risk of bias compared a topical agent with a placebo. Four of these trials randomised by
individual and one by cluster. When results from the five trials were combined, the risk ratio (RR) was 0.78 (95% CI 0.47 to 1.31; P
value 0.35) indicating no overall beneficial effect of the topical agents. When the cluster randomised trial was omitted from the analysis,
use of topical agents reduced the pressure ulcer incidence by 36%; RR 0.64 (95% CI 0.49 to 0.83; P value 0.0008).
Four trials (561 participants), all of which were of high or unclear risk of bias, showed that dressings applied over bony prominences
reduced pressure ulcer incidence; RR 0.21 (95% CI 0.09 to 0.51; P value 0.0006).
Authors’ conclusions
There is insufficient evidence fromRCTs to support or refute the use of topical agents applied over bony prominences to prevent pressure
ulcers. Although the incidence of pressure ulcers was reduced when dressings were used to protect the skin, results were compromised by
the low quality of the included trials. These trials contained substantial risk of bias and clinical heterogeneity (variations in populations
and interventions); consequently, results should be interpreted as inconclusive. Further well designed trials addressing important clinical,
quality of life and economic outcomes are justified, based on the incidence of the problem and the high costs associated with pressure
ulcer management.
P L A I N L A N G U A G E S U M M A R Y
Dressings or topical agents for preventing pressure ulcers
Pressure ulcers, sometimes known as bedsores or pressure sores, commonly occur in people who cannot, or find it difficult to, move
themselves. Pressure ulcers are hard to heal, so it is important to try to prevent them from occurring in the first place. Various cream
and lotions (topical agents) have been used for this purpose; the idea is that pressure ulcers are less likely to occur when the skin is
healthy and nourished. A number of different types of dressings are also used to protect the skin from damage. We reviewed studies that
compared topical agents or dressings with other methods for preventing pressure ulcers. We found nine trials that investigated these that
included 1501 people. These showed that the evidence concerning the use of topical agents or dressings for preventing pressure ulcers
is not clear. The reason why the evidence is not clear is because the quality of trials was low and most had manufacturer sponsorship,
which introduces potential biases, such as overestimating the effectiveness of the product. Consequently, further trials are needed to
confirm results of this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical agent versus placebo combined studies for preventing pressure ulcers
Patient or population: Patients at risk of developing pressure ulcers
Settings: Hospitals
Intervention: Topical agent versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Topical agent versus
placebo
Pressure ulcer inci-
dence
Observat ion
Follow-up: 3 to 24
weeks
Study population RR 0.78
(0.47 to 1.31)
940
(5 studies)
⊕©©©
very low1,2,3,4
251 per 1000 195 per 1000
(118 to 328)
M oderate
313 per 1000 244 per 1000
(147 to 410)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
1 Lim ited information provided for generat ion of allocat ion sequence, allocat ion concealment and outcome evaluat ion. Three
of the f ive trials had incomplete report ing and the majority received manufacturer sponsorship
3
D
re
ssin
g
s
a
n
d
to
p
ic
a
l
a
g
e
n
ts
fo
r
p
re
v
e
n
tin
g
p
re
ssu
re
u
lc
e
rs
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
3
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
2 There were variat ions in both the intervent ion products and the control products. Dif ferent measures (some unvalidated)
were used to assess the stage of the pressure ulcer
3 Most of the part icipants were geriatric pat ients in hospitals and nursing homes. Other groups at high risk (such as those
unable to reposit ion and intensive care pat ients) were not represented
4 Conf idence intervals were wide due to small sample sizes
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B A C K G R O U N D
Description of the condition
A pressure ulcer is defined as localised injury to the skin, under-
lying tissue or both, usually over a bony prominence, as a result
of pressure, or pressure in combination with shear. A number of
contributing or confounding factors are also associated with pres-
sure ulcers; the significance of these factors has yet to be eluci-
dated (EPUAP/NPUAP 2009). Prevalence rates range from 8.8%
to 53.2% (Gallagher 2008; Moore 2012) and incidence rates vary
from7% to 71.6% (Moore 2011; Scott 2006;Whittington 2004).
Pressure ulcers are generally staged 1, 2, 3 and 4, according to
the depth of tissue damage, with grade 1 being the least severe
and grade 4 indicating full-scale tissue destruction (Moore 2005)
(Appendix 1). The most common anatomical sites for pressure
ulcers to occur are the sacrum and the heels, and the majority are
stage 1 or stage 2 in severity (Gallagher 2008;Gethin 2005;Moore
2000; Moore 2011).
Pressure ulcers occur in people who do not have the ability to
reposition themselves in order to relieve pressure on bony promi-
nences. This ability is often diminished in the very old, the mal-
nourished and those with an acute illness (Wann-Hansson 2008).
It is important to note, however, that although pressure ulcers of-
ten occur in older individuals, other populations, such as those
with spinal cord injury and hospital patients exposed to prolonged
periods of immobility (for example during long surgical proce-
dures) also have high pressure ulcer incidence (Gallagher 2008;
Sheerin 2005). Certain patients, with stage 1 pressure ulcers, are
also at increased risk of the pressure ulcer progressing to a stage
4 (Vanderwee 2009). For example, individuals with hypotension,
contractures, or a history of cerebral vascular accident, tend to
develop more serious pressure ulcers despite standard preventive
measures (Vanderwee 2009). Thus, a clear focus on the adoption
of targeted prevention strategies is important at the outset, so that
the individual is not exposed to pressure ulcers in the first instance
(Sullivan 2013; Vanderwee 2009).
Pressure ulcers impact negatively on an individual’s quality of life.
Indeed, the emotional, physical, mental and social domains of life
are all profoundly affected (Spilsbury 2007). Pain is described as
one of the most significant problems for individuals with pressure
ulcers (Spilsbury 2007). Importantly, many of the treatment reg-
imens adopted exacerbate these adverse effects (Hopkins 2006).
Thus, it is important to consider the impact of prevention and
treatment strategies on the individual, and to choose those that
will reduce discomfort and enhance rehabilitation wherever pos-
sible (Gorecki 2009). Pressure ulcers are also associated with in-
creased mortality (Kroger 2008). Whether this relates to the fact
that pressure ulcers occur in a population that is for the most part
debilitated, with a high incidence of co-morbidities, or whether it
relates to the presence of a pressure ulcer alone, remains unclear
(Brown 2003; Tarnowski 2013; Thomas 1996). However, a recent
cohort study suggests an almost two-fold increase in death among
those with pressure ulcers when compared to their matched coun-
terparts who do not have pressure ulcers (Landi 2007).
Pressure ulcers impose a significant financial burden on healthcare
systems, indeed Dealey 2012 suggests that the total annual cost
for pressure ulcer management in the UK is GBP 1.4 to 2.1 billion
annually, or 4% of the total UK healthcare expenditure. In Aus-
tralia, the mean hospital costs for pressure ulcers are estimated at
AUD 296.05 million (Graves 2005a). In the United States, hos-
pital costs for adults with a diagnosis of pressure ulcers totaled
USD 11.0 billion in 2006 (Russo 2006). That pressure ulcers are
an expensive problem has also been reported in the Netherlands
where they have been found to be the third most costly issue
for healthcare services. (Haalboom 2000). This is not due to the
cost of medication or surgical interventions, but due to prolonged
hospitalisation and the intensive nursing care required. Indeed,
pressure ulcers are associated with significantly higher mean un-
adjusted hospital costs per episode of care. (USD 37,288 versus
USD 13,924, P value 0.0001) (Allman 1999).
The exact mechanisms by which externally applied mechanical
forces (pressure and shear) result in pressure ulcer development
are not clearly understood (Stekelenburg 2007). Pressure is equal
to force divided by area, the same amount of force applied to a
small area, when compared to a bigger area, will result in greater
pressure (O’Callaghan 2007). Shear is the mechanical stress act-
ing parallel to a plane of interest, such as is seen when a person
sits up in bed and then begins to slide down the bed, with his/
her skin remaining in the same place because it sticks to the bed
linen (Collier 2006). It is postulated that, in the presence of pro-
longed pressure and shear forces, there are fourmechanismswithin
three functional units that lead to pressure ulcer development.
The functional units are the capillaries, the interstitial (between
cells) spaces and the cells (Nixon 2005). The mechanisms are local
ischaemia (lack of oxygen) Kosiak 1959, reperfusion injury (in-
jury to cells caused by the restoration of blood supply to tissues)
(Tsuji 2005), impaired interstitial (between cells) fluid flow, and
lymphatic drainage (Reddy 1981) and sustained deformity of cells
(Stekelenburg 2007). These mechanisms, alone or combined, re-
duce the oxygen and nutrient supply to cells, impair the removal of
waste products following cell metabolism, leading to cell damage
and inevitable tissue destruction. It is important to note, however,
that none of the process described will have any relevance unless
the individual is exposed to sustained external mechanical forces.
Therefore, as pressure/shear are the causative factors, reducing the
amount and duration of pressure/shear will decrease the likelihood
of pressure ulcer development.
Description of the intervention
Pressure ulcer prevention is now an expanding industry and in-
volves a range of interventions, such as nutritional care (Langer
2003), skin care, use of pressure redistribution surfaces (McInnes
5Dressings and topical agents for preventing pressure ulcers (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2011), and repositioning (Moore 2011). Selection of an appropri-
ate topical therapy (i.e. those applied to the skin) is also believed to
contribute to pressure ulcer prevention strategies, and such thera-
pies are widely used within the clinical setting (Butcher 2009), in
combination with other preventive strategies.
A topical agent is a cream or an ointment that is applied directly
to the skin (Reddy 2006). Whereas a dressing is a therapeutic
or protective material applied to a wound to promote healing,
it may also be used to protect the skin from damage (Butcher
2009). Dressings are classified into groups depending on their
characteristics (Moore 2006).
For the purposes of pressure ulcer prevention, the types of dressings
used are primarily those that afford protection to the skin, such
as:
• semi-permeable film dressings (a thin polyurethane
membrane coated with a layer of an acrylic adhesive);
• hydrocolloid dressings (a dressing containing a dispersion of
gelatin, pectin and carboxy-methylcellulose together with other
polymers and adhesives forming a flexible wafer); or
• foam dressings (an open cell, hydrophobic, polyurethane
foam sheet) (Dressings.org 2010).
Topical agents may be used in isolation, but are more likely to be
impregnated in dressings, or used in combination with dressings.
How the intervention might work
The EPUAP/NPUAP 2009 guidelines suggest that use of film
dressings may help to protect the skin against the adverse effects of
friction, furthermore, they suggest that use of foam dressings may
protect parts of the body at risk of shear injury. It has also been
suggested that the application of topical agents directly to the skin
will protect against the adverse affects of friction (Reddy 2006).
Both friction and shear are included as risk factors for pressure ul-
cer development in the Braden pressure ulcer risk assessment scale
(Bergstrom 1987). However, the recent EPUAP/NPUAP pressure
ulcer prevention and management guidelines have removed fric-
tion from their definition of a pressure ulcer (EPUAP/NPUAP
2009), suggesting that although friction forces contribute to tissue
damage, they are not a contributory factor in pressure ulcer devel-
opment (EPUAP/NPUAP 2009). Nonetheless, the International
Review 2010 argues that because friction and shear are closely
linked, friction should be discussed in the context of pressure ulcer
development (and thus pressure ulcer prevention).One hypothesis
upon which the use of dressings/topical agents for the prevention
of pressure ulcers is based, relates to their role in the reduction
of friction forces (Butcher 2009). Furthermore, Lahmann 2011
identified that friction was a causative factor in the development
of superficial wounds resembling grade 1 and 2 pressure ulcers,
whereas, pressure and shear were responsible for the development
of deeper ulcers (grades 3 and 4). Earlier work by Kottner 2009
supports this argument, in classifying ulcers as superficial - pre-
dominantly caused by friction, or deep - predominantly caused by
pressure. Therefore, there is debate regarding the relative contri-
bution of friction to the development of pressure ulcers, nonethe-
less, friction does contribute to tissue damage, which in itself is
problematic for patients and carers, and this is where topical agents
and dressings may play a role.
Why it is important to do this review
The use of dressings for preventing pressure ulcers is discussed in
the literature and in international pressure ulcer prevention guide-
lines. To date, the level of evidence to support these recommenda-
tions has not been systematically assessed (Butcher 2009). The use
of adjunct therapies (for example, dressings, creams, or lotions)
as part of prevention strategies adds to the overall costs, therefore
it is important to explore whether use of these therapies provides
potential benefit to patients (Moore 2008).
O B J E C T I V E S
Toevaluate the effects of dressings and topical agents for preventing
pressure ulcers, in people of any age without existing pressure
ulcers, but considered to be at risk of developing a pressure ulcer,
in any care setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies that randomise individuals (randomised controlled trials
(RCTs)) or that randomise by groups (cluster-RCTs), were eligible
for inclusion.
Types of participants
People of any age, both adults and children, without a pressure
ulcer, but considered to be at risk of developing a pressure ulcer,
in any care setting.
Types of interventions
The primary intervention was any wound dressing or topical agent
applied to the skin at any frequency with the aim of preventing the
development of a pressure ulcer. We included RCTs comparing
the use of dressings, topical agents, or topical agents with dress-
ings, compared with a different dressing, topical agent, combined
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topical agent and dressing, no intervention or standard care or any
other intervention as a comparator, with the aim of preventing the
development of a pressure ulcer.
Types of outcome measures
Primary outcomes
Pressure ulcer incidence (the proportion of people developing any
new pressure ulcer(s) of any grade). For the purpose of this re-
view a pressure ulcer was defined as a localised injury to the skin,
underlying tissue or both, usually over a bony prominence, as a
result of pressure, or pressure in combination with shear. This re-
view included all grades of pressure ulcer damage, following the
definition of the EPUAP/NPUAP (EPUAP/NPUAP 2009). We
accepted the definition of the method of assessment of pressure
ulcer damage as outlined by trial authors.
Secondary outcomes
• Stage of any new pressure ulcer(s).
• Time to ulcer development.
• Costs of interventions.
• Quality of life as measured by a validated scale.
• Pain at dressing change, measured using a validated scale.
• Acceptability of the intervention (or satisfaction) with
respect to patient comfort.
• Adverse events.
• Length of hospital stay.
Search methods for identification of studies
Electronic searches
In February 2013 we searched the following electronic databases
for RCTs or cluster-RCTs which evaluated the use of dressings or
topical agents for the prevention of pressure ulcers:
• The Cochrane Wounds Group Specialised Register
(searched 21 February 2013);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2013, Issue 1);
• Ovid MEDLINE (2005 to February Week 2 2013);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, February 20, 2013);
• Ovid EMBASE (2005 to 2013 Week 07);
• EBSCO CINAHL (2005 to 15 February 2013).
We used the following search strategy in the Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor: [Biological Dressings] explode all trees 61
#2 MeSH descriptor: [Occlusive Dressings] explode all trees 435
#3 MeSH descriptor: [Hydrogels] explode all trees 211
#4 MeSH descriptor: [Alginates] explode all trees 170
#5 dressing*:ti,ab,kw 2468
#6 (hydrocolloid* or alginate* or hydrogel* or foam or bead or
film or films or tulle or gauze or non-adherent or non adherent):
ti,ab,kw 4780
#7 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
8199
#8 MeSH descriptor: [Administration, Topical] explode all trees
11774
#9 #7 and #8 449
#10 (topical near/2 antibiotic*):ti,ab 274
#11 MeSH descriptor: [Anti-Infective Agents, Local] explode all
trees 1473
#12 MeSH descriptor: [Anti-Inflammatory Agents] explode all
trees 10106
#13 MeSH descriptor: [Glucocorticoids] explode all trees 3075
#14 #12 or #13 12314
#15 #8 and #14 1724
#16 (topical near/2 (steroid* or corticosteroid* or glucocorti-
coid*)):ti,ab,kw 1314
#17 MeSH descriptor: [Estrogens] explode all trees 1247
#18 #8 and #17 122
#19 (topical near/2 (oestrogen or estrogen)):ti,ab,kw 29
#20 MeSH descriptor: [Enzymes] explode all trees 21699
#21 #8 and #20 353
#22 (topical near/2 enzym*):ti,ab,kw 4
#23MeSHdescriptor: [Growth Substances] explode all trees 2398
#24 #8 and #23 38
#25 (topical near/2 growth factor*):ti,ab,kw 13
#26 MeSH descriptor: [Collagen] explode all trees 1645
#27 #8 and #26 70
#28 (topical near/2 collagen):ti,ab,kw 14
#29 (topical near/2 silver):ti,ab 16
#30 MeSH descriptor: [Ointments] explode all trees 1588
#31 (ointment* or lotion* or cream*):ti,ab,kw 6662
#32 MeSH descriptor: [Honey] explode all trees 80
#33 honey.ti,ab,kw 5
#34 (topical next (agent* or preparation* or therap* or treat-
ment*)):ti,ab,kw 1778
#35 (#1 or #2 or #3 or #4 or #5 or #6 or #9 or #10 or #11 or #15
or #16 or #18 or #19 or #21 or #22 or #24 or #25 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34) 17393
#36 MeSH descriptor: [Pressure Ulcer] explode all trees 495
#37 pressure next (ulcer* or sore*):ti,ab,kw 872
#38 decubitus next (ulcer* or sore*):ti,ab,kw 89
#39 (bed next sore*) or bedsore*:ti,ab,kw 48
#40 (#36 or #37 or #38 or #39) 935
#41 #35 and #40 293
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 2. We combined
the Ovid MEDLINE search with the Cochrane Highly Sensitive
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Search Strategy for identifying randomised trials in MEDLINE:
sensitivity- and precision-maximising version (2008 revision) (
Lefebvre 2011).We combined the EMBASE search with the Ovid
EMBASE filter developed by the UK Cochrane Centre (Lefebvre
2011). We combined the CINAHL searches with the trial filters
developed by the Scottish Intercollegiate Guidelines Network (
SIGN 2010). There were no restrictions with respect to language,
date of publication or study setting .
We searched the following clinical trials registries on June 4 2012:
• Clinical Trials.gov
• Internationsl Clinical Trials Registry Platfom (ICTRP)
Searching other resources
We searched the bibliographies of all retrieved and relevant pub-
lications identified by these strategies for further studies. We con-
tacted manufacturers of dressings (n = 15) used in the prevention
of pressure ulcers, as identified in the British National Formulary
(BNF 2011), and experts in the field to ask for information rele-
vant to this review.
Data collection and analysis
Selection of studies
Two review authors independently assessed titles and, where avail-
able, abstracts of the studies identified by the search strategy against
the eligibility criteria for inclusion in the review. We obtained full
versions of potentially relevant studies and the two review authors
independently screened these against the inclusion criteria. Any
differences in opinion were resolved by discussion and, where nec-
essary, reference to the Cochrane Wounds Group editorial base.
Data extraction and management
Two review authors independently extracted data from eligible
studies using a data extraction sheet. Specifically, we extracted the
following information:
• author, title, source;
• date of study, study’s geographical location;
• care setting;
• inclusion/exclusion criteria;
• patient characteristics;
• balance of groups at baseline;
• study design details;
• method of randomisation;
• allocation concealment;
• sample size calculation and sample size;
• intervention details, concurrent interventions;
• type of dressing and frequency of dressing change;
• use of additional dressing materials;
• patient length of hospital stay;
• outcome measures;
• blinding (of the patient/outcome assessor);
• length of follow-up;
• loss to follow-up;
• results;
• intention-to-treat analysis; and
• conclusions as reported by the study authors.
Any differences in opinion were resolved by discussion and, where
necessary, with reference to theCochraneWounds Group editorial
base. If data were missing from reports, we attempted to contact
study authors to obtain the missing information.
Assessment of risk of bias in included studies
Two review authors independently assessed the included studies
using the Cochrane Collaboration tool for assessing risk of bias
(Higgins 2011a). This tool addresses six specific domains: namely,
sequence generation, allocation concealment, blinding, incom-
plete outcome data, selective outcome reporting and other issues
(e.g. extreme baseline imbalance) see Appendix 3 for details of
criteria on which the judgement were based. We assessed blinding
and completeness of outcome data for each outcome separately.
Measures of treatment effect
For dichotomous outcomes, we calculated risk ratio (RR) plus
95% confidence intervals (CI). If continuous outcomes had been
reported, we would have calculated mean difference (MD) plus
95% confidence intervals. We would also have analysed time-to-
event data (e.g. time to ulceration) as survival data, using the
appropriate analytical method (as per the Cochrane Handbook for
Systematic Reviews of Interventions version5) (Deeks 2011). If time-
to-event data had been incorrectly presented as continuous data,
we would have presented the data in a narrative format in the
review.
Summary of findings tables
To assess the overall body of evidence, we developed two Summary
of findings tables (one for each comparison - topical agents and
dressings), using GRADE profilerT M . The quality of the body of
evidence was assessed against five principle domains 1) limitations
in design and implementation; 2) indirectness of evidence or gen-
eralisability of findings; 3) inconsistency of results - for example
unexplained heterogeneity and inconsistent findings; 4) impreci-
sion of results where confidence intervals are wide; and 5) other
potential biases, for example publication bias or high manufac-
turer involvement (Schunemann 2011) .
Unit of analysis issues
There was one unit of analysis issue and one potential unit of
analysis issue. In the (Houwing 2008) trial, a cluster design was
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used and data was analysed as though allocation was by individual.
In the Nakagami 2007 trial, patients acted as their own controls.
That is, the intervention dressing was randomly applied to the left
or right greater trochanter and, although there was a potential for
a unit of analysis issue with the design, this did not occur as no
pressure ulcers occurred in either group.
Dealing with missing data
If there was evidence of missing data, we contacted the trial au-
thors to request the information. Where trial authors could not
provide missing data, we assessed the risk of bias of the missing
data and decided if the missing data were of ’low’ or ’high’ risk
of bias according to our risk of bias criteria (Higgins 2011a). Or,
if data were considered to be missing at random, we analysed the
available information. Where outcome data were missing, we used
an available-case analysis, based on the numbers of participants
for whom outcome data were known.
Assessment of heterogeneity
We explored clinical heterogeneity by examining potentially in-
fluential factors, e.g. type of topical agent or dressing, care set-
ting or participant characteristics, such as level of mobility. We as-
sessed statistical heterogeneity using the I2 statistic (Higgins 2003).
This examines the percentage of total variation across studies due
to clinical and/or methodological heterogeneity rather than to
chance. Values of I2 over 75% indicate a high level of heterogene-
ity.
Assessment of reporting biases
We completed a ’Risk of bias’ table for each eligible study and
presented an assessment of risk of bias using a ’Risk of bias’ sum-
mary figure (Figure 1) which presents the judgements in a cross-
tabulation. This display of internal validity indicates the weight
the reader may give to the results of each study.
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Figure 1. Study flow diagram.
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Data synthesis
We conducted a structured narrative summary of the studies re-
viewed. We entered quantitative data into RevMan 5 (RevMan
2011), and conducted analyses using RevMan software. For di-
chotomous outcomes, we calculated risk ratio (RR) plus 95% CI.
We carried out statistical pooling on groups of studies that were
considered to be sufficiently similar. Where heterogeneity was ab-
sent or low (I2 = 0% to 25%) we used a fixed-effect model; if
there was evidence of heterogeneity (I2 more than 25%), we used
a random-effects model. If heterogeneity was very high (I2 over
75%) we did not pool the data (Higgins 2003). We included the
cluster randomised controlled trial (Houwing 2008) in the data
synthesis, even though the study was analysed as if the randomisa-
tion was performed on individuals rather than clusters. To explore
the effect of this approach, we conducted separate analyses with
and without the cluster trial.
Subgroup analysis and investigation of heterogeneity
If sufficient data had been available we would have undertake the
following subgroup analysis:
• type of setting (community, hospital, inpatient, outpatient).
However, all studies were conducted in hospital settings.
Sensitivity analysis
Wewere to have performed a sensitivity analysis by excluding stud-
ies at high risk of bias. In this sensitivity analysis, we would have
only included studies that were assessed as having a low risk of bias
in all key domains, namely adequate generation of the randomi-
sation sequence, adequate allocation concealment and blinding of
outcome assessor, for the estimates of treatment effect. However,
no studies met these criteria.
R E S U L T S
Description of studies
Results of the search
The search yielded a total of 139 citations and two further papers
were identified when JW contacted 15 dressings manufacturers
enquiring about further potential papers. Both review authors ex-
amined the abstracts of all papers independently to assess for po-
tential relevance. After excluding duplicates, 19 trials appeared to
meet the inclusion criteria and full texts were retrieved. A further
10 trials were subsequently excluded; reasons for their exclusion
are shown in Figure 1 and are detailed in the Characteristics of
excluded studies.
Included studies
See the Characteristics of included studies table.
Nine trials with a total of 1501 participants were included in the
review (Green 1974; Han 2011; Houwing 2008; Kalowes 2012;
Nakagami 2007; Qiuli 2010; Smith 1985; Torra i Bou 2005; Van
Der Cammen 1987), one of which was a cluster RCT (Houwing
2008). Contact was attempted with seven investigators to seek
additional information. We were unable to locate Green 1974,
no response was received from the authors of Han 2011, Qiuli
2010, Torra i Bou 2005 or Van Der Cammen 1987, but Houwing
2008 andKalowes 2012 responded andprovided answers to several
questions.
Participants
The mean age of participants in seven of the trials varied between
67.5 and 86 years (Green 1974; Houwing 2008; Kalowes 2012;
Nakagami 2007; Van Der Cammen 1987; Smith 2010; Torra i
Bou 2009). In a trial of spinal injury patients, the mean age was
56 years (Han 2011). The participants in the Qiuli 2010 study
were aged between 55 and 80 years.
Three of the trials were conducted in the UK (Green 1974; Smith
2010; Van Der Cammen 1987), one in China (Han 2011), two
in Japan (Nakagami 2007; Qiuli 2010), one in Spain (Torra i Bou
2009), one in the Netherlands (Houwing 2008), and one in the
USA (Kalowes 2012).
An inclusion criterion for four trials was that the individuals were
at high risk of pressure ulcer development according to the Braden
pressure ulcer risk assessment scale (Bergstrom 1987; Houwing
2008; Kalowes 2012; Nakagami 2007; Torra i Bou 2009). For one
trial the individuals had a Norton pressure sore risk-assessment
scale score of between five and 14 (meaning high or very high risk)
(Norton 1975; Van Der Cammen 1987), and for a further trial
the participants had a Waterlow score of 18-23 (meaning high or
very high risk) (Qiuli 2010; Waterlow 1985). For the remaining
trials other non-validated risk assessment methods were used. For
exampleGreen 1974 usedwhat was defined as a ‘clinical risk score’,
Smith 2010 included ‘patients with intact skin’ and it was unclear
what criteria were used for the Han 2011 trial.
Four studies included elderly hospital or nursing home patients
(Green 1974; Houwing 2008; Nakagami 2007; Smith 1985); one
included internal medicine patients at high risk of pressure injury
(Torra i Bou 2005). Participants in the Han 2011 trial were ad-
mitted with a posterior spinal injury; in the Van Der Cammen
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1987 trial participants were hospitalised and chair-bound; partici-
pants in the Kalowes 2012 trial were nursed in a medical/surgical/
trauma intensive care unit or a cardiac intensive care unit, and the
participants in the Qiuli 2010 trial were nursed in a neurosurgical
department.
Interventions
See “Additional tables; Table 1’ for the composition of the topical
agents and dressings.
Topical applications
In the Green 1974 study the intervention was a lotion described
as ”active“, containing hexachlorophane 0.5%, saturated hydro-
carbons (squalene (Cosbiol 3%) and glyoxyle diureide), allantoin
0.2%, antioxidants, lanolin, fatty acids, fatty acid esters, fatty al-
cohols, preservatives and distilled water. For the control group,
a lotion described as ”inert“ containing lanolin, fatty acids, fatty
acid esters, fatty alcohols, preservatives, distilled water andmineral
oils, was applied. The lotions were applied manually to pressure
areas (sacral, trochanteric, heel and shoulder and other areas, as
indicated). Excess friction was avoided. The participants’ skin was
inspected every two hours, and, if the participant was incontinent,
the skin was washed with soap and water, then dried, and the rele-
vant lotion applied. In the absence of incontinence, routine wash-
ing and reapplication of lotion was carried out every six hours.
In the Smith 1985 study the topical application for the interven-
tion group was Conotrane, which contains silicone cream, 20%
dimethicone 350 and a broad spectrum antiseptic (0.05% hydrar-
gaphen). For the control group the topical application was de-
scribed as a bland cream known as Unguentum. For both groups,
as part of the routine skin care regimen, the skin of the participants
was washed when required, with water, then dried thoroughly and
the ointment applied.
In the Houwing 2008 study the topical application for the inter-
vention group wasmassage using a “DMSO-cream.” TheDMSO-
cream consisted of 5% dimethyl sulfoxide in Vaseline-cetomacro-
gol cream; participants also had a 30o position change every six
hours. For the placebo group the topical application was a three-
minute massage of the buttock, heel, and ankle regions with an
indifferent cream (Vaseline-cetomacrogol), combined with a 30o
position change every six hours for four weeks. For the control
group, no topical application was applied, but the participants had
a 30o position change every six hours for four weeks.
In the Torra i Bou 2005 study the topical application for the inter-
vention group was Mepentol, a hyperoxygenated fatty acid com-
pound consisting of oleic acid, palmitic acid, stearic acid, palmi-
toleic acid, linoleic acid, gamma linoleic acid, arachidonic acid,
and eicosenoic acid. For the control group, the topical application
was a compound consisting of trisostearin (99.4%) and perfume
(0.6%). In both groups, the topical application was applied twice
daily to at least three areas of the body, sacrum, trochanter and
heels.
Finally, in the Van Der Cammen 1987 study the topical applica-
tion was Prevasore, which contains hexyl nicotinate, zinc stearate,
isopropyl myristate, Dimethicone 350, cetrimide and glycol. For
the control group the topical applicationwasDermalexwhich con-
tains hexachlorophane, squalene and allantoin. In both groups,
the participants’ buttocks and sacral areas were washed and dried
and the topical application was applied at least twice daily and
again after changing, if the individual was wet or soiled.
In all of the studies using topical applications, no additional dress-
ings were applied, the topical application was applied to the skin
and the skin was then left bare.
Dressings
In the Han 2011 study the intervention was a polyurethane film
and foam dressing (Hang’ huier transparent strip and foam dress-
ing). This was applied to the pressure areas of the participants dur-
ing surgery. The control group did not have any dressings applied.
In the Nakagami 2007 study, the intervention was a dressing,
known as PPD (pressure ulcer preventive dressing). This consists
of a skin adhesive layer (hydrocolloid) containing an intercellular
lipid-ceramide, a support layer (urethane film) and an outer layer
of multi-filament nylon fibres. The dressing was applied to either
the right or left greater trochanter (depending on randomisation)
of the participant. The dressing was replaced weekly. No dressing
was applied in the control arm of the study.
In the Qiuli 2010 study the intervention was a soft silicone, self-
adherent, bordered foam dressing applied to the integral skin site
of pressed bone protuberance. The frequency of dressing changes
was not mentioned in the paper. For the control group, massage
of the site of bone protuberance was undertaken at each patient-
turning episode (two- to three-hourly). The duration of massage
was not mentioned in the paper. Both groups were nursed on air
cushion mattresses and repositioned every two to three hours.
In the final study of Kalowes 2012, the intervention was a soft sili-
cone, self-adherent, bordered foamdressing applied to the subjects’
sacrum. The dressing was changed every three days, or as needed.
No dressing was applied to the skin of the control group partic-
ipants. Both groups were nursed according to the SKIN bundle
(Surface, Keep turning, Incontinence and Nutrition) (Gibbons
2006).
Outcomes
All the studies included the development of a pressure ulcer as their
primary outcome.Two used the validated scale of EPUAP 1999
(Houwing 2008; Nakagami 2007). Han 2011 reported use of
an international measurement for pressure ulcers titled “WCET”;
Green 1974 used a five-point scale; Smith 1985 used the classi-
fication of Barbarel 1977; while Van Der Cammen 1987 used a
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five-point scale; finally, Torra i Bou 2005, Qiuli 2010 and Kalowes
2012 did not identify the classification system used.
Ethics and consent
No information about ethics approval or participant consent was
provided by Green 1974, Han 2011, Kalowes 2012, Qiuli 2010
or Van Der Cammen 1987. Although Smith 1985 had ethics ap-
proval, it was not reported whether participants consented. Infor-
mation on ethics and consent for the remaining studies was not
available (Houwing 2008; Nakagami 2007; Torra i Bou 2005).
Funding
Seven of the nine trials reported receiving support from the man-
ufacturers of the interventional product (Green 1974; Han 2011;
Kalowes 2012; Nakagami 2007; Smith 1985; Torra i Bou 2005;
Van Der Cammen 1987). Sponsorship for the Houwing 2008
study came from ZonMw (Ministry of Health, Welfare and Sport
and the Netherlands Organisation for Scientific Research). Qiuli
2010 did not state whether sponsorship was received. In the
Nakagami 2007 trial, investigators were involved in developing
the dressing used in the study. The corresponding author in the
Van Der Cammen 1987 trial was an employee of the company
producing the intervention product.
Excluded studies
We excluded a total of 10 studies. Six studies were not RCTs
(Callaghan 1998; Declaire 1997; Garcia Fernandez 2005; Hsu
2011; Huang 2009; Smith 2010); one was a cross-over study
(Duimel-Peeters 2007); one was a cost analysis from an unpub-
lished study with limited information (Torra i Bou 2009); and
two considered interventions for treating pressure ulcers rather
than preventing them (Kuisma 1987; Stoker 1990). See the
Characteristics of excluded studies table for details.
Risk of bias in included studies
See Figure 2 for the summary of the risk of bias and Figure 3
for the graph of the risk of bias of the included studies. Several
studies had inadequate reporting, which limited our assessment of
potential bias (see Figure 2; and Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
13Dressings and topical agents for preventing pressure ulcers (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Methods used for generating the allocation sequence were unclear
in all but one of the trials (Houwing 2008).
Allocation concealment
Methods used for concealing the group allocation were unclear in
all trials.
Blinding
All of the ’topical agent’ trials were blinded to investigators, pa-
tients and outcome assessors (Green 1974; Houwing 2008; Smith
1985; Torra i Bou 2005; Van Der Cammen 1987). Difference in
the appearance of dressings in the remaining trials made blind-
ing impossible (Han 2011; Kalowes 2012; Nakagami 2007; Qiuli
2010).
Incomplete outcome data
Outcome data reporting was judged to be complete in five trials
(Han 2011; Houwing 2008; Nakagami 2007; Qiuli 2010; Smith
1985). In the remaining four studies (Green 1974; Kalowes 2012;
Torra i Bou 2005; Van Der Cammen 1987), 9% to 48% of those
recruited were excluded from the analysis, so the studies were
judged to be at high risk of bias.
Selective reporting
All of the trials provided information on the outcomes identified
in their trial methods, so were considered to be at low risk of
reporting bias. None of the trials had registered their protocol on
a trials registry database.
Other potential sources of bias
In the Smith 1985 study, 33% more participants in the placebo
group were incontinent for urine, and 25%more were incontinent
for faeces, than in the treatment group and this was not adjusted
for in the analysis. We had only limited information about the
methods used in the Han 2011 study, and data from a conference
presentation to interpret for the Kalowes 2012 study. It is possible
that there may have been biases about which we were unaware. Fi-
nally in the Nakagami 2007 and Van Der Cammen 1987 studies,
the investigators were part of the group that developed the inter-
vention products, so introducing a potential for bias, for example,
overestimating the treatment effect.
Effects of interventions
See: Summary of findings for the main comparison Topical
agent compared with placebo for preventing pressure ulcers;
Summary of findings 2 Dressing compared with no dressing
combined studies for preventing pressure ulcers
See Summary of findings for the main comparison and Summary
of findings 2 for a summary of main outcomes.
All of the studies reported data for our primary outcome; pressure
ulcer incidence. Five trials investigated the effects of topical agents
and four trials the effects of dressings. In line with these differences,
we used two comparisons, one for topical applications and one for
dressings regardless of dressing type. It was not possible to combine
numerical data for our secondary outcomes, so these results are
presented in narrative form.
How the results are presented and what the terms
mean
Results for dichotomous variables are presented as risk ratios (RR)
with 95% CI. Risk ratio is the ratio of the risk of the event of
interest (e.g. pressure ulcers developed) in the experimental group
divided by the risk of this event in the control group and indicates
the chances of pressure ulcer development for people in the exper-
imental group compared with the control group (Higgins 2011b).
A risk ratio of one means there is no difference between two groups
in terms of their risk of pressure ulcer development, whereas a risk
ratio of greater than one, or of less than one, usually means that
use of a specific topical agent or dressing either increases (risk ratio
greater than one) or decreases (risk ratio less than one) the risk
of pressure ulcer development (Higgins 2011b). As, by definition,
the risk of an event occurring in the control group is 1, then the
RR reduction associated with using an experimental treatment is
1-RR. The RR indicates the relative benefit of a therapy but not
the actual benefit, that is, it does not take into account the num-
ber of people who would have developed a pressure ulcer anyway,
without the intervention (Higgins 2011b).
Comparison 1: Topical agent compared with placebo
(five trials, 940 participants)
Primary outcome
Incidence of pressure ulcers
Five trials were included in this comparison.
The study by Green 1974, with a three-week follow-up period,
found a pressure ulcer incidence of 25% (n = 19/76; with ery-
thema 17%, n = 13/76; superficial sores 7.8%, n = 6/76) in the
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intervention group and a pressure ulcer incidence of 34% (n = 31/
91; with erythema 13.2%, n = 12/91; superficial sores 20.8%, n =
19/91) in the control group. The intervention group were treated
with an active lotion and the control were treated with an inert
lotion. There was no statistically significant difference in pressure
ulcer incidence between the two groups (RR 0.73, 95% CI 0.45
to 1.19; P value 0.21) (Analysis 1.1).
The study by Smith 1985, had a 24-week follow-up period, and
noted a pressure ulcer incidence of 27% (n = 35/129) in the ex-
perimental group treated with Conotrane. Conversely, a pressure
ulcer incidence of 36.4% (n = 47/129) was noted in the control
group treated with a bland cream, known as Unguentum. The
majority of pressure ulcers (87%) in both groups were described
as superficial. There was no statistically significant difference in
pressure ulcer incidence between the two groups (RR 0.74, 95%
CI 0.52 to 1.07; P value 0.11) (Analysis 1.1).
The study by Van Der Cammen 1987, with a follow-up of three
weeks, noted a pressure ulcer incidence of 1.8% (n = 1/54) in those
treatedwith Prevasore (the intervention treatment) comparedwith
a pressure ulcer incidence of 6.0% (n = 3/50) in those treated
with Dermalex (the control treatment).There was no statistically
significant difference in pressure ulcer incidence between the two
groups (RR 0.31, 95% CI 0.03 to 2.87; P value 0.30) (Analysis
1.1).
The study by Torra i Bou 2005, with a follow-up of 30 days,
compared an intervention ofMepentol with a placebo compound.
The trial authors identified a pressure ulcer incidence of 7.3% (n =
12/164) in the intervention group, compared with a pressure ulcer
incidence of 17.37% (n = 29/167) in the placebo group. There
was a statistically significant difference in pressure ulcer incidence
between those treated with the topical agent (Mepentol) and the
placebo (RR 0.45, 95% CI 0.22 to 0.80; P value 0.008) (Analysis
1.1).
The study by Houwing 2008, with a follow-up of four weeks,
explored the impact of three different regimens on the incidence
of pressure ulcers. Participants were treated with either the in-
tervention treatment of massage with a DMSO-cream combined
with a six-hourly, 30o position change; or a placebo intervention
consisting of a three-minute massage with what the trial authors
referred to as an indifferent cream combined with a six-hourly,
30o position change; or a control intervention, where no creams
were applied to participants’ skin, but they did have a six-hourly,
30o position change. Houwing 2008 identified a pressure ulcer
incidence of 62.1% (n = 18/29) in the intervention group, 31.3%
(n = 10/32) in the placebo group and 38.9% (n = 7/18) in the
control group. There was no statistically significant difference in
pressure ulcer incidence between the intervention and the control
group (RR 1.60, 95% CI 0.84 to 3.04; P value 0.16) (Analysis
2.1). There was no statistically significant difference in pressure
ulcer incidence between the placebo and control group (RR =
0.80, 95% CI 0.37 to 1.74; P value 0.58) (Analysis 3.1). There
was a statistically significant difference in pressure ulcer incidence
between the intervention and the placebo group (RR = 1.99, 95%
CI 1.10 to 3.57; P value 0.02) (Analysis 4.1), this difference was
in favour of the placebo group which meant that the intervention
increased the number of pressure ulcers that developed compared
to the placebo group.
Houwing 2008 used cluster randomisation and did not allow for
the clustering in the analysis, so we have reported the combined
results with and without this study. When results were combined
with inclusionofHouwing 2008, the overall RRwas 0.78 (95%CI
0.47 to 1.31; P value 0.35) indicating no overall beneficial effect of
the topical agents. There was a high level of heterogeneity in this
analysis (72%), which persisted when a random-effects model was
used (Analysis 5.1; Figure 4).When resultswere combinedwithout
Houwing 2008, the level of heterogeneity was 0%, the overall RR
was 0.64 (95% CI 0.49 to 0.83; P value 0.0008) (Analysis 5.2;
Figure 5), showing a statistically significant beneficial effect of the
topical agents, however, this should be interpreted with caution
owing to the potential bias in the included trials.
Figure 4. Forest plot of comparison: Topical agent versus placebo, outcome: 5.1 Pressure ulcer incidence.
(Houwing study included)
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Figure 5. Forest plot of comparison: Topical agent versus placebo, outcome: 5.2 Pressure ulcer incidence.
(Houwing study excluded)
Secondary outcomes
Stage of any new pressure ulcer(s)
In the Smith 1985 trial (258 participants) the group that used
a silicone cream application found there was no difference in
the incidence of third or fourth stage pressure ulcers compared
with placebo (stage 3: intervention 5/129 (3.8%); placebo 4/129
(3.0%) and stage 4: intervention 0/129 (0.0%); placebo 1/129
(0.7%)).
Time to ulcer development
Two trials assessed time to the development of a new pressure
ulcer (501 participants) (Green 1974; Torra i Bou 2005). In the
Green 1974 trial, ulcers appeared approximately one day later in
the intervention group than in the placebo group (intervention 9.8
days versus placebo 8.7 days (whether these are means or medians
was not stated in the trial report). Kaplan-Meier survival curves,
used in the Torra i Bou 2005 trial, indicated that pressure ulcer
developmentwas delayed among people in the intervention group;
the reported P value was 0.0054.
Adverse events
Only Green 1974 reported data about adverse events. In their
study of 170 participants, two people in the intervention arm
developed erythematous eruptions of the skinwhere the creamhad
been applied. A patch test indicated hypersensitivity to the product
(Dermalex™ which is an emollient based cream consisting of
mainly hexachlorophane).
Cost
Costs in the Torra i Bou 2005 trial were based on the cost of
the intervention product (Mepentol) only, this was reported to be
approximately EUR 9.3 per month, no comparison cost data were
provided.
Comparison 2: Dressing compared with no dressing
(four trials, 444 participants)
Primary outcome
Incidence of pressure ulcers
Four trials were included in this comparison.
TheNakagami 2007 study had a three-week follow-upperiod. Par-
ticipants were treated with a dressing, known as PPD, applied to
either the right or the left trochanter. Particpants acted as their own
controls, i.e. no dressing was applied to the opposite trochanter.
No pressure ulcers developed in either group (intervention n = 0/
37; control n = 0/37). This study is prone to unit of analysis error,
as two sides of each patient were randomised to intervention and
control however no pressure ulcers developed in either group. The
trial authors reported the presence of persistent erythema in 5.5%
(n = 2/37) of the intervention group and in 29.7% (n = 11/37) of
the control group. We have interpreted the presence of persistent
erythema as stage 1 pressure ulcer. There was a statistically signif-
icant difference in pressure ulcer incidence between the interven-
tion and the control groups in favour of the dressing (RR 0.18,
95% CI 0.04 to 0.76; P value 0.02) (Analysis 6.1).
The Han 2011 study, had a 72-hour follow-up period. The in-
tervention group, treated with Kang’ huier transparent strip and
foam dressing (a polyurethane film and foam dressing) had a pres-
sure ulcer incidence of 4.1% (n = 2/29). The control group had no
dressings applied and had a pressure ulcer incidence of 9.8% (n =
5/51). There was no statistically significant difference in pressure
ulcer incidence between the two groups (RR 0.70, 95% CI 0.15
to 3.40; P value 0.66) (Analysis 6.1).
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The Qiuli 2010 study had a seven-day follow-up period. The
intervention group (n = 26), had a dressing applied at the integral
skin site of pressed bone protuberance; pressure ulcer incidence in
this group was zero. The control group (n = 26) had no dressing
applied, but hadmassage on the site of bone protuberance; pressure
ulcer incidence in this group was 11.5% (n = 3/26). There was
no statistically significant difference in pressure ulcer incidence
between the two groups (RR 0.14, 95% CI 0.01 to 2.63; P value
0.19) (Analysis 6.1).
The Kalowes 2012 study followed up participants while in the
intensive care unit, where the mean length of stay was 6.5 days
(range 0 to 120 days). The intervention group had a dressing
applied to the skin covering the sacral area.The control group
had no dressing applied. The incidence of pressure ulcers in the
intervention group was 0.5% (n = 1/169), and the incidence in
the control group was 4% (n = 7/166). The trial authors reported
a statistically significant difference between the groups (P value
0.001), however, RevMan analysis did not replicate this and found
no statistical difference between the groups (RR 0.14, 95% CI
0.02 to 1.13; P value 0.06) (Analysis 6.1).
When data were combined from these four studies (Han 2011;
Kalowes 2012; Nakagami 2007; Qiuli 2010), they showed that
dressings applied over bony prominences reduced the pressure ul-
cer incidence P value to 0.0006; RR 0.21 (95% CI 0.09 to 0.51)
(Analysis 7.1; Figure 6). Although the difference was statistically
significant, the studies are at high or uncertain risk of bias and
firm conclusions cannot be drawn from this analysis.
Figure 6. Forest plot of comparison: Dressing versus no dressing, outcome: 7.1 Pressure ulcer incidence.
Secondary outcomes
Stage of any new pressure ulcer(s)
In the Kalowes 2012 trial (335 participants), using a dressing ap-
plied to the skin covering the sacral area, yielded no statistically
significant difference in the incidence of deep tissue injury com-
pared to the group with no dressing (deep tissue injury: inter-
vention 1/169 (0.5%); placebo 1/166 (0.6%). The remaining six
pressure ulcers occurred in the placebo group and were classified
as: unstageable: 2/166 (1%) and stage 2: 4/166 (2%).
Pre-defined outcomes sought but not reported
No studies reported on quality of life, pain at dressing change, or
length of hospital stay. Stage of any new pressure ulcer(s); time to
ulcer development; cost and adverse events were poorly described.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Dressing versus no dressing combined studies for preventing pressure ulcers
Patient or population: Patients at risk of developing pressure ulcers
Settings: Hospital
Intervention: Dressing versus no dressing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Dressing versus
no dressing combined
studies
Pressure ulcer inci-
dence
Observat ion
Follow-up: > 48 h to 3
weeks
Study population RR 0.21
(0.09 to 0.51)
561
(4 studies)
⊕⊕©©
low1,2,3,4
93 per 1000 19 per 1000
(8 to 47)
M oderate
107 per 1000 22 per 1000
(10 to 55)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
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1 There was no descript ion of sequence generat ion or allocat ion concealment in any of the trials. Intervent ion blinding was
not possible. Outcome assessment was not blinded in two studies and unclear in the remaining two trials. Three of the
four trials received manufacturer support
2 Although heterogeneity was low, three types of dressings were used, the composit ion of each was quite dif f erent
3 Part icipants in all of the trials were at very high risk of pressure ulcer development (drawn f rom intensive care/ cardiac care
units or geriatric units), so results may not be generalisable to all hospitalised pat ients
4 Three of the four trials were small, with fewer than 100 part icipants. This resulted in wide conf idence intervals around the
ef fect size, creat ing uncertainty around the precision of the result .
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D I S C U S S I O N
This review identified nine trials exploring the impact of dressings
(n = 4) or topical agents (n = 5) on the incidence of pressure ul-
cers. When the four dressings trials were combined (Han 2011;
Kalowes 2012; Nakagami 2007; Qiuli 2010), dressings applied
over bony prominences were found to reduce pressure ulcer in-
cidence. However, these studies have a high, or uncertain risk of
bias, thus, firm conclusions cannot be drawn from this finding.
However, pooled analyses could be interpreted as indicating the
potential for a likely effect given that all studies favoured the use of
a dressing and the relatively narrow CI but further, independently
funded trials are required to confirm these findings.
A key question to consider is whether dressings can contribute to
pressure and shear force reduction, in terms of their ability to afford
greater protection of bony prominences (Butcher 2009). Pressure
must be present for a pressure ulcer to develop, the effect of pres-
sure is time dependent, and the time it takes a pressure ulcer to de-
velop will be influenced by the general condition of the individual
(Moore 2012). Immobility is of significance, which makes logical
sense, as people who are unable to reposition themselves in order
to relieve pressure will be exposed to prolonged external mechani-
cal forces (Moore 2012). Furthermore, when pressure is not evenly
distributed, then it is the point pressure (i.e. the pressure applied
on a specific area of the body) that causes damage. Additionally,
the thickness and tone of the subcutaneous tissues influence the
relationship between externally applied forces and corresponding
interstitial pressures (Bader 1990). Thus, when a person is exposed
to prolonged externally-applied mechanical forces, an aspect of
pressure ulcer prevention strategies is to redistribute the force over
the greatest area, thereby reducing the magnitude of pressure. The
principles upon which pressure redistribution is based (apart from
actually changing the person’s position) are immersion and envel-
opment (International Review 2010). Immersion is the ability of
the product to allow the person to sink into it, and envelopment
refers to how well the product moulds to the shape of the body
contours (for example the heel) (International Review 2010). At
its essence, immersion allows for pressure to spread out over the
surrounding areas, thus redistributing it rather than alleviating it
(Baranoski 2008). For dressings, their relatively small size (area)
means that their potential for pressure redistribution is minimal,
bearing in mind that pressure is equal to force divided by area.
Dressings will only play a small part in the prevention of pressure
ulcers, as the key causative factor is pressure and shear, thus re-
lief of pressure and shear is fundamental to preventing pressure
ulcers. Logically, dressings cannot relieve pressure they can only
contribute to dissipating pressure, although to what effect remains
unclear. Indeed, dressings, which are generally relatively thin in
composition and of a small size, can only have a limited role in
pressure redistribution, as they cannot readily adhere to the princi-
ples of immersion and envelopment. Furthermore, consideration
needs to be given to the effects that the edges of the dressing have
on interface pressures (the pressures between the skin and the edge
of the dressing). When data were combined from the four studies
(Han 2011; Kalowes 2012; Nakagami 2007; Qiuli 2010), they
showed that dressings applied over bony prominences reduced the
pressure ulcer incidence, however, due to the high or uncertain
risk of bias, firm conclusions cannot be drawn from this analysis.It
is unlikely that the reduction in incidence relates to the pressure/
shear reduction ability of the dressings, rather may relate to the
ability to reduce friction forces. A further issue of concern is the
role of skin assessment in pressure ulcer prevention. The EPUAP/
NPUAP guidelines highlight the importance of including skin as-
sessment as part of the overall pressure ulcer prevention strategy of
the organisation (EPUAP/NPUAP 2009). Specifically, they state
that staff should include a complete skin assessment as part of the
risk screening of patients. In addition, the skin should be assessed
regularly to determine any changes in condition, with the fre-
quency of this assessment increased, if alteration in skin condition
is noticed (EPUAP/NPUAP 2009). It is unlikely that dressings
will be removed very regularly to facilitate this assessment, as to
do so may cause discomfort to the patient and may be perceived
as contributing to increased costs. Thus, this may reduce the prac-
ticality of dressing use for pressure ulcer prevention.
Friction is commonly referred to as the action of two objects rub-
bing against each other, for example a person’s heel and the sheet
covering the bed International Review 2010. It has been suggested
that keeping the skin moisturised is important because this allows
the heel, for instance, to move more freely over the sheet, and
so reduces friction forces. This review included five studies that
explored the effects of topical agents in pressure ulcer incidence
(Green 1974; Houwing 2008; Smith 1985; Torra i Bou 2005; Van
Der Cammen 1987). The Houwing 2008 trial was responsible for
high heterogeneity. In that study, outcomes favoured the placebo
arm, whereas all other trials favoured the intervention product.
Therefore, when results were combined with Houwing 2008 in-
cluded, the findings showed no overall beneficial effect of the top-
ical agents. When results were combined without Houwing 2008,
the problems with heterogeneity were removed, and the findings
suggested a statistically significant beneficial effect of the topical
agents. However, as Houwing 2008 was the only trial without
manufacturer funding, these results should be interpreted with
caution owing to the potential bias in the included trials. An al-
ternative explanation for the heterogeneity, may be that Houwing
2008 was the only cluster RCT. A further problem with trying
to understand the implications of our review of topical applica-
tions was that many of the studies were quite old and most in-
cluded products that are not commercially available. None of the
trials used commonly used creams, such as Sorbelene or aqueous
cream as comparators, products that are widely used for mois-
turising the skin. Four of the studies mentioned repositioning as
a key component of pressure ulcer prevention strategies within
the trials (Green 1974; Houwing 2008; Torra i Bou 2005; Van
Der Cammen 1987). Smith 1985 stated that the intervention was
21Dressings and topical agents for preventing pressure ulcers (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
integrated into the staffs’ usual routine skin care regimens. This
suggests that use of topical agents alone, may be insufficient to
prevent pressure ulcers. The precise role of dressings and topical
agents, therefore, remains unclear.
Summary of main results
Development of new pressure ulcers
This systematic review examined the evidence from randomised
controlled trials (RCTs) that focused on the effects of interven-
tions aimed at reducing the development of new pressure ulcers.
Two categories of interventions were used, creams or topical ap-
plications applied to the skin, and dressings placed over bony
prominences such as the sacrum and hips. Most of the interven-
tion creams contained essential fatty acids because of their known
role in wound healing (McCusker 2010). However, evidence of
the benefit of topical applications remains inconclusive, with no
clear benefit shown for topical products. Further information is
required to clarify the effect of topical agents on the prevention of
pressure ulcers.
In four small studies, dressings applied over bony prominences
appeared to confer a slight prophylactic affect, with a 79% risk
reduction in the incidence of newpressure ulcers in people assigned
to the group in which a dressing was used. However, the wide
confidence intervals (0.09 to 0.51) around the effect size and the
high risk of bias evident all studies indicate that additional research
is required to confirm these results.
Other outcomes
There was limited evidence from one study to suggest that the
application of a topical agent may delay the development of a new
pressure ulcer, but not prevent its occurrence (Torra i Bou 2009).
As with other outcomes, this result requires further investigation
before any recommendation about the effect of topical agents on
timing of pressure ulcer development can be made. The review
did not identify any other benefit for topical agents or dressings
over a placebo topical agent or standard care.
Overall completeness and applicability of
evidence
Most of the studies focused on the primary outcome, develop-
ment of a new pressure ulcer, in populations of elderly hospitalised
or nursing-home patients. While these groups represent many of
those at risk of pressure injury, other high risk groups, such as peo-
ple with paraplegia and other immobile people also require inves-
tigation (Alderden 2011). The included studies failed to provide
adequate economic evaluations. Healthcare providers need such
data, to be able to assess the cost/benefit implications of new in-
terventions adequately. Only one study mentioned adverse events
(Green 1974), and none provided information about other im-
portant patient-related outcomes such as quality of life or accept-
ability of the product.
Quality of the evidence
Limitations in study design and implementation
Risk of bias was assessed according to six components: sequence
generation; allocation concealment; blinding; selective outcome
reporting, incomplete follow-up and other potential biases. The
methodological quality of most of the RCTs was poor, with lim-
itations in a number of these domains (Figure 4). The Nakagami
2007 study is prone to unit of analysis error, as two sides of each
patient were randomised to intervention and control.
Indirectness of evidence
The review was limited by variations in both the experimental and
the control interventions. For example, the constituents of the top-
ical applications varied between studies, as did the placebo cream,
and in the trials that compared dressings with standard care, the
dressings were made of different materials. Consequently, the ev-
idence was restricted to indirect comparisons between these var-
ied interventions. Additionally, a number of the high-risk groups
were not represented within the included studies, so the evidence
may be regarded as indirect for other patients (such as intensive
care patients and other immobile people). Taken together, these
limitations restrict confident decision making with regard to the
use of topical agents and dressings to prevent the development of
pressure ulcers.
Unexplained heterogeneity or inconsistency of results
We combined results of studies that investigated the effect of top-
ical agents on the development of pressure injury, despite a high
level of heterogeneity between studies (albeit within our pre-de-
fined cut-off point for pooling data). One study was responsible
for the high heterogeneity (Houwing 2008). In that study, out-
comes favoured the placebo arm, whereas all other trials favoured
the intervention product. The Houwing 2008 trial was the only
one that did not report manufacturer support.
Imprecision of results
Confidence intervals were wide in both of the pooled outcomes
indicating a high level of uncertainty around the effect size (Figure
4; Figure 6). Further research is, therefore, very likely to have an
important impact on the confidence of the estimate of effect for
both topical agents and dressings.
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Publication bias
We feel confident that our comprehensive electronic searches iden-
tified all existing, published randomised controlled trials address-
ing the review question. It is theoretically possible, though un-
likely, that we did not manage to locate some potentially eligible
studies. In line with Cochrane policy, this review will be updated
in future, and any studies identified that meet the inclusion crite-
ria will be included at that stage.
Potential biases in the review process
We followed clearly described procedures to prevent potential bias
in the review process. This included a careful literature search and
the methods we used were transparent and reproducible. None of
the authors has any conflict of interest. It is possible that trials
published in journals that were outside our search strategy may
have been missed.
Agreements and disagreements with other
studies or reviews
Although there have beenmany systematic reviews and studies ad-
dressing treatment of pressure ulcers, there has been less attention
paid to preventing their occurrence. The prevention reviews that
exist have focused on other interventions, such as support surfaces
(McInnes 2011), risk assessment tools (Moore 2008), and nutri-
tional interventions (Langer 2003). One overview of pressure ul-
cer prevention strategies did include topical applications (Reddy
2006). Our results concur with Reddy 2006 who concluded that
”The incremental benefit of specific topical agents over simple
moisturizers . . . remains unclear“.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Pressure ulcers are a relatively common and important complica-
tion of hospitalisation and the application of creams or other topi-
cal agents is frequently used as an intervention to prevent pressure
ulcers from forming. However, there is insufficient evidence from
independently funded clinical trials to support or refute the use of
topical agents for this purpose.
There is also a paucity of evidence from well conducted ran-
domised controlled trials (RCTs) about the effectiveness of dress-
ings to prevent pressure ulcers. Although there was a reduced in-
cidence of pressure ulcers when dressings were used to protect the
skin, results were compromised by the low-quality of included tri-
als. These trials contained substantial risk of bias (e.g. inadequate
randomisation) and clinical heterogeneity (variations in popula-
tions and interventions); consequently, our results should be in-
terpreted as inconclusive.
Implications for research
The evidence base for use of topical agents and dressings to pre-
vent pressure ulcers is limited, despite the wide use of these inter-
ventions. Further trials are justified, based on the incidence of the
problem and the high costs associated with pressure ulcer man-
agement. Future trials should be large enough to showmeaningful
differences; include patient-related outcomes such as product ac-
ceptability, adverse events and quality of life, and economic eval-
uations to assist healthcare managers to make rational decisions.
Standard, validated tools should be used tomeasure outcomes such
as pressure ulcer staging, and quality of life.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Green 1974
Methods Double blind RCT, with 3-week follow-up, method of randomisation not stated
Participants 319 geriatric participants from 6 geriatric departments in the UK
Interventions Topical agent trial
Group 1 (intervention): active lotion containing: hexachlorophane 0.5%, saturated hy-
drocarbons (squalene (Cosbiol 3%) and
glyoxyle diureide), allantoin 0.2%, antioxidants, lanolin, fatty acids, fatty acid esters,
fatty alcohols, preservatives and distilled water
Group 2 (control): inert lotion containing: lanolin, fatty acids, fatty acid esters, fatty
alcohols, preservatives, distilled water and mineral oils
Lotions applied with fingers to pressure areas (sacral, trochanteric, heel and shoulder and
other areas as indicated). Excess friction avoided. Skin inspected every 2 h, participant
turned and changed if soiled, washed with soap and water, skin dried and lotion applied
after each cleansing. In the absence of incontinence, routine washing and reapplication
of lotion was carried out every 6 h
Bed cradles used for all participants to keep the weight of the bedding off the feet and
lower legs
Participants with a score of 10 or less (clinical at risk score) were nursed on a large cell
alternating pressure mattress
Outcomes The outcome of interest was pressure ulcer incidence, noted as either erythema or su-
perficial sores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence for participants: blinded
Comment: quote: ”The active and inert lo-
tions were similar in appearance and tex-
ture. They were randomly dispensed in
identical plastic squeeze bottles to avoid
possible bias of application“
Evidence for personnel: blinded
Comment: quote: ”The active and inert lo-
tions were similar in appearance and tex-
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Green 1974 (Continued)
ture. They were randomly dispensed in
identical plastic squeeze bottles to avoid
possible bias of application, or other nurs-
ing procedures“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evidence for outcomes: blinded
Comment: quote: ”The active and inert lo-
tions were similar in appearance and tex-
ture. They were randomly dispensed in
identical plastic squeeze bottles to avoid
possible bias of application, or other nurs-
ing procedures, and of the research nurses
observations“
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT not conducted, 152 participants ex-
cluded
Selective reporting (reporting bias) Low risk Evidence: pressure ulcers described as ery-
thema or superficial in the results
Comment: pressure ulcers of greater than
grade 2 were grounds for discontinuation
of trial
Other bias Low risk
Han 2011
Methods RCT, follow-up 72 hours.
Participants 100people admitted for posterior spinal surgery in Shandong,China.The study excluded
people with previous skin disease, those undergoing emergency surgery, and those with
operation time of < 3 h. Follow-up at 24 h and 72 h post surgery
Interventions Dressing trial
Intervention group: Kang’ Huier transparent strip and foam dressing
Control group: routine operating room protective measures
Outcomes Pressure ulcer incidence
Notes Authors state that the 2 pressure ulcers in the intervention group occurred outside the
treated area
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Evidence for outcomes: not described
Comment: states only that participants were randomly
grouped. But authors did not explain how the sequence was
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Han 2011 (Continued)
generated
Allocation concealment (selection bias) Unclear risk Evidence for outcomes: not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence for outcomes: blinding impossible due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence for outcomes: blinding impossible due to the
nature of the intervention.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 100 participants enrolled and all accounted for
in the results
Selective reporting (reporting bias) Low risk Evidence for outcomes: the only outcome pre-specified
was ’pressure sore’.
Other bias Unclear risk Comment: We had only the most important data inter-
preted. It is possible that there may have been biases about
which we are unaware
Houwing 2008
Methods Cluster RCT, 4-week follow-up, randomly assigned at ward level not at participant level.
Exact method of randomisation not stated
Participants 79 participants at risk of development of pressure ulcers, in 8 nursing homes in the
Netherlands
Interventions Topical agent trial
Group 1 (intervention): massage using a “DMSO-cream.” This cream consisted of
5% dimethyl sulfoxide in Vaseline-cetomacrogol cream, combined with a 30o position
change. This procedure was repeated every 6 h for 4 weeks
Group 2 (placebo): 3-minute massage of the buttock, heel, and ankle regions with an
indifferent cream (Vaseline-cetomacrogol) combined with a 30o position change. This
procedure was repeated every 6 h for 4 weeks
Group 3 (control): 30o position change, repeated every 6 h for 4 weeks
Outcomes Pressure ulcer incidence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Throw of a dice (additional information
from the author)
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Houwing 2008 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence for participants: stated as dou-
ble blind
Comment: stated as double blind
Evidence for personnel: stated as double
blind
Comment: stated as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evidence for outcomes: blinded
Comment: quote: ”presence of a pressure
ulcer confirmed by two external observers“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: none excluded
Selective reporting (reporting bias) Low risk Evidence: outcome measure was the pres-
ence of a pressure ulcer
Comment: thiswas reported by the authors
Other bias Low risk
Kalowes 2012
Methods Prospective RCT
Participants 367 people nursed in amedical/surgical/trauma intensive care unit and a cardiac intensive
care unit
Interventions Dressing trial
Group 1 (intervention): silicone foam dressing and SKIN care bundle
Group 2 (control): SKIN care bundle
Outcomes Pressure ulcer incidence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomly assigned“
Allocation concealment (selection bias) Unclear risk Not stated
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Kalowes 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, but difference in the appearance of dressing makes
blinding impossible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Evidence: 367 participants enrolled into the study, analysis con-
ducted on 335 participants
Selective reporting (reporting bias) Unclear risk Evidence: outcome measure was the presence of a pressure ulcer
Comment: this was reported by the authors
Nakagami 2007
Methods RCT, 3-week follow-up, method of randomisation not stated
Participants 37 participants, aged ≥ 65 with a Braden score of < 15, in a 500 bed geriatric hospital
in Japan
Interventions Dressing trial
Group1: PPD(dressingwith skin adhesive layer (hydrocolloid), a support layer (urethane
film) and an outer layer of multi filament nylon fibres). Applied to either the right or
the left trochanter. PPD replaced every week
Group 2: participants acted as their own control, i.e. no dressing was applied to the
opposite trochanter
Outcomes Incidence of pressure ulcer
Incidence of persistent erythema
Notes Pressure ulcer classification system not clearly described
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Evidence for participants: not blinded
Comment: quote: “impossible due to the
type of intervention”
Evidence for personnel: not blinded
Comment: quote: “impossible due to the
32Dressings and topical agents for preventing pressure ulcers (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nakagami 2007 (Continued)
type of intervention”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Evidence for outcomes: not blinded
Comment: quote: ”test area outlined so
that the dressing applied back to the same
area“
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT conducted
Selective reporting (reporting bias) Low risk Evidence: all outcomes reported in the pa-
per were those outlined by the authors
Other bias Unclear risk Comment: investigators were part of the
group that developed the PPD
Qiuli 2010
Methods RCT, 7-day follow-up, method of randomisation not stated
Participants 52 participants, Waterlow score18-23, in a department of neurosurgery, Harbin, China
Interventions Intervention: mepilex dressing applied to weight-bearing bony areas
Control: massage of bony areas
Both groups turned 2-3 hourly and nursed on air cushion beds
Outcomes Incidence of pressure ulcer
Notes Pressure ulcer classification system not described
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, but difference in the appearance
of dressing makes blinding impossible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated
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Qiuli 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants included in the final anal-
ysis
Selective reporting (reporting bias) Low risk Evidence: all outcomes reported in the pa-
per were those outlined by the authors
Smith 1985
Methods Double-blind RCT, 24-week follow-up, method of randomisation not stated
Participants 258 elderly continuing-care patients, UK
Interventions Topical agent trial
Group 1 (intervention): Conotrane (silicone cream; 20% dimethicone 350; and a broad
spectrum antiseptic (0.05% hydrargaphen)), skin washed, dried and ointment applied
Group 2 (control): Unguentum cream, skin washed, dried and ointment applied
Outcomes Pressure ulcer incidence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence for participants: no mention
within the article
Comment: quote: The placebo ointment
had been suitably scented so that it was in-
distinguishable from the active preparation
Evidence for personnel: no mention
within the article
Comment: quote: ”The placebo ointment
had been suitably scented so that it was
indistinguishable from the active prepara-
tion“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evidence for outcomes: no mention
within the article
Comment: quote: ”The placebo ointment
had been suitably scented so that it was
indistinguishable from the active prepara-
tion“
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Smith 1985 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence: results table 1: of 258 partici-
pants
Comment: data presented related to those
who entered the study
Selective reporting (reporting bias) Low risk Evidence: all outcomes reported in the pa-
per were those outlined by the authors
Other bias Unclear risk Comment: one third more participants
in the placebo group were incontinent of
urine and one quarter more were incon-
tinent of faeces when compared with the
treatment group
Torra i Bou 2005
Methods Multicentre double-blind RCT, randomised code in a closed envelope, 30-day follow-
up
Participants 380 individuals at risk of pressure ulcers, in Spain
Interventions Topical agent trial
Group 1 (intervention): Mepentol, a hyperoxygenated fatty acid compound (consisting
of: oleic acid, palmitic acid, stearic acid, palmitoleic acid, linoleic acid, gamma-linoleic
acid, arachidonic acid, and eicosenoic acid), applied twice daily to at least 3 areas of the
body, sacrum, trochanter, heels
Group 2 (control): compound consisting of trisostearin (99.4%) and perfume (0.6%)
applied twice daily to at least 3 areas of the body, sacrum, trochanter, heels
Outcomes Pressure ulcer incidence
Cost
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: did not state how the randomi-
sation sequence was generated
Allocation concealment (selection bias) Unclear risk Evidence: coded randomisation in closed
envelope
Comment: did not state that the envelopes
were opaque
35Dressings and topical agents for preventing pressure ulcers (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Torra i Bou 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence for participants: blinded
Comment: quote: ”only the coordinator
had access to the packaging codes so neither
the investigator nor patient knew which
group a patient had been allocated to“
Evidence for personnel: blinded
Comment: quote: ”only the coordinator
had access to the packaging codes so neither
the investigator nor patient knew which
group a patient had been allocated to“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Evidence for outcomes: blinded
Comment: quote: ”only the coordinator
had access to the packaging codes so neither
the investigator nor patient knew which
group a patient had been allocated to“
Incomplete outcome data (attrition bias)
All outcomes
High risk Evidence: ITT not conducted, results pre-
sented for 167 and 164 participants and
not for the original 380 enrolled
Selective reporting (reporting bias) Low risk Evidence: all outcomes reported in the pa-
per were those outlined by the authors
Other bias Low risk
Van Der Cammen 1987
Methods Double-blind RCT, method of randomisation not stated
Participants 120 chair-bound participants, with a Norton score 5-14, from the Department of Geri-
atric Medicine, UK
Interventions Topical agent trial
Group 1 (intervention): buttocks and sacral areas washed and dried, and Prevasore (Hexyl
nicotinate, zinc stearate, isopropyl myristate, Dimethicone 350, cetrimide and glycol)
applied at least twice daily, and after changing, if wet or soiled
Group 2 (control): buttocks and sacral areas washed and dried, and Dermalex (hex-
achlorophane, squalene and allantoin) applied at least twice daily, and after changing, if
wet or soiled
Outcomes Pressure ulcer incidence
Notes Data presented for 104 participants
Risk of bias
Bias Authors’ judgement Support for judgement
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Van Der Cammen 1987 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Evidence for participants: Quote ” . . .
this formulationwas compared, in a double
blind clinical trial . . “
Evidence for personnel: Quote ” . . . this
formulation was compared, in a double
blind clinical trial . . . “
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Evidence for outcomes: not mentioned
Comment: although unclear, it is proba-
ble that outcome assessment was blinded,
given that the trial was ’double blinded’
Incomplete outcome data (attrition bias)
All outcomes
High risk Evidence: ITT not conducted
Comment: Data presented relate to the
number who concluded the study exclud-
ing those withdrawn
Selective reporting (reporting bias) Low risk Evidence: All outcomes reported in the pa-
per are those outlined by the authors
Other bias Unclear risk Comment: Corresponding author mem-
ber of staff of themanufacturer of the prod-
uct under investigation
Abbreviations
< = less than
≥ = more than, or equal to
h = hour(s)
ITT = intention-to-treat analysis
PPD = pressure ulcer preventative dressing
RCT = randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Callaghan 1998 Not an RCT
Declaire 1997 Not an RCT
Duimel-Peeters 2007 Cross-over trial
Garcia Fernandez 2005 Review of a previous study by Torra i Bou
Hsu 2011 Quasi-experimental
Huang 2009 Not an RCT
Kuisma 1987 Treatment intervention not prevention
Smith 2010 Not an RCT
Stoker 1990 Treatment intervention not prevention
Torra i Bou 2009 Cost analysis from an unpublished study, presented at a Pressure Ulcer Advisory Panel meeting in 2002.
No abstract available
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D A T A A N D A N A L Y S E S
Comparison 1. Topical agent versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Topical agent versus control (Houwing)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.84, 3.04]
Comparison 3. Placebo versus control (Houwing)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.37, 1.74]
Comparison 4. Topical agent versus placebo (Houwing)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 1 61 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [1.10, 3.57]
39Dressings and topical agents for preventing pressure ulcers (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 5. Topical agent versus placebo combined studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 5 940 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.47, 1.31]
2 Pressure ulcer incidence 4 879 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.83]
Comparison 6. Dressing versus no dressing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 7. Dressing versus no dressing combined studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pressure ulcer incidence 4 561 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.09, 0.51]
Analysis 1.1. Comparison 1 Topical agent versus placebo, Outcome 1 Pressure ulcer incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 1 Topical agent versus placebo
Outcome: 1 Pressure ulcer incidence
Study or subgroup Topical agent Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Green 1974 19/76 31/91 0.73 [ 0.45, 1.19 ]
Smith 1985 35/129 47/129 0.74 [ 0.52, 1.07 ]
Torra i Bou 2005 12/164 29/167 0.42 [ 0.22, 0.80 ]
Van Der Cammen 1987 1/54 3/50 0.31 [ 0.03, 2.87 ]
0.01 0.1 1 10 100
Favours topical agent Favours placebo
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Analysis 2.1. Comparison 2 Topical agent versus control (Houwing), Outcome 1 Pressure ulcer incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 2 Topical agent versus control (Houwing)
Outcome: 1 Pressure ulcer incidence
Study or subgroup Topical agent Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Houwing 2008 18/29 7/18 100.0 % 1.60 [ 0.84, 3.04 ]
Total (95% CI) 29 18 100.0 % 1.60 [ 0.84, 3.04 ]
Total events: 18 (Topical agent), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours topical agent Favours control
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Analysis 3.1. Comparison 3 Placebo versus control (Houwing), Outcome 1 Pressure ulcer incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 3 Placebo versus control (Houwing)
Outcome: 1 Pressure ulcer incidence
Study or subgroup Placebo Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Houwing 2008 10/32 7/18 100.0 % 0.80 [ 0.37, 1.74 ]
Total (95% CI) 32 18 100.0 % 0.80 [ 0.37, 1.74 ]
Total events: 10 (Placebo), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours control
Analysis 4.1. Comparison 4 Topical agent versus placebo (Houwing), Outcome 1 Pressure ulcer incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 4 Topical agent versus placebo (Houwing)
Outcome: 1 Pressure ulcer incidence
Study or subgroup Topical Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Houwing 2008 18/29 10/32 100.0 % 1.99 [ 1.10, 3.57 ]
Total (95% CI) 29 32 100.0 % 1.99 [ 1.10, 3.57 ]
Total events: 18 (Topical), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Topical Favours control
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Analysis 5.1. Comparison 5 Topical agent versus placebo combined studies, Outcome 1 Pressure ulcer
incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 5 Topical agent versus placebo combined studies
Outcome: 1 Pressure ulcer incidence
Study or subgroup Topical agent Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Green 1974 19/79 31/91 24.6 % 0.71 [ 0.43, 1.15 ]
Houwing 2008 18/29 10/32 22.3 % 1.99 [ 1.10, 3.57 ]
Smith 1985 35/129 47/129 27.2 % 0.74 [ 0.52, 1.07 ]
Torra i Bou 2005 12/164 29/167 21.3 % 0.42 [ 0.22, 0.80 ]
Van Der Cammen 1987 1/60 3/60 4.6 % 0.33 [ 0.04, 3.11 ]
Total (95% CI) 461 479 100.0 % 0.78 [ 0.47, 1.31 ]
Total events: 85 (Topical agent), 120 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 14.31, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours topical agent Favours placebo
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Analysis 5.2. Comparison 5 Topical agent versus placebo combined studies, Outcome 2 Pressure ulcer
incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 5 Topical agent versus placebo combined studies
Outcome: 2 Pressure ulcer incidence
Study or subgroup Topical agent Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Green 1974 19/79 31/91 26.8 % 0.71 [ 0.43, 1.15 ]
Smith 1985 35/129 47/129 43.7 % 0.74 [ 0.52, 1.07 ]
Torra i Bou 2005 12/164 29/167 26.7 % 0.42 [ 0.22, 0.80 ]
Van Der Cammen 1987 1/60 3/60 2.8 % 0.33 [ 0.04, 3.11 ]
Total (95% CI) 432 447 100.0 % 0.64 [ 0.49, 0.83 ]
Total events: 67 (Topical agent), 110 (Placebo)
Heterogeneity: Chi2 = 2.82, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00078)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours topical agent Favours placebo
Analysis 6.1. Comparison 6 Dressing versus no dressing, Outcome 1 Pressure ulcer incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 6 Dressing versus no dressing
Outcome: 1 Pressure ulcer incidence
Study or subgroup Dressing No dressing Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Han 2011 2/29 5/51 0.70 [ 0.15, 3.40 ]
Kalowes 2012 1/169 7/166 0.14 [ 0.02, 1.13 ]
Nakagami 2007 2/37 11/37 0.18 [ 0.04, 0.76 ]
Qiuli 2010 0/26 3/26 0.14 [ 0.01, 2.63 ]
0.01 0.1 1 10 100
Favours dressing Favours no dressing
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Analysis 7.1. Comparison 7 Dressing versus no dressing combined studies, Outcome 1 Pressure ulcer
incidence.
Review: Dressings and topical agents for preventing pressure ulcers
Comparison: 7 Dressing versus no dressing combined studies
Outcome: 1 Pressure ulcer incidence
Study or subgroup Dressing No dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Han 2011 2/49 5/51 18.5 % 0.42 [ 0.08, 2.05 ]
Kalowes 2012 1/169 7/166 26.7 % 0.14 [ 0.02, 1.13 ]
Nakagami 2007 2/37 11/37 41.6 % 0.18 [ 0.04, 0.76 ]
Qiuli 2010 0/26 3/26 13.2 % 0.14 [ 0.01, 2.63 ]
Total (95% CI) 281 280 100.0 % 0.21 [ 0.09, 0.51 ]
Total events: 5 (Dressing), 26 (No dressing)
Heterogeneity: Chi2 = 0.96, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00057)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours dressing Favours no dressing
A D D I T I O N A L T A B L E S
Table 1. Intervention topical agents and dressings
AUTHOR YEAR TOPICAL AGENTS DRESSINGS
Green 1974 Dermalex™: consisting of hexachlorophane 0.5%,
squalene (Cosbiol 3%), and allantoin 0.2%, lanolin,
fatty acids, fatty alcohols, and antioxidants
Han 2011 Kang’ huier transparent strip and foam dressing
Houwing 2008 DMSO-cream: consisting of 5% dimethyl sulfoxide
in Vaseline-cetomacrogol cream
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Table 1. Intervention topical agents and dressings (Continued)
Kalowes 2012 Soft silicone, self adherent, bordered foam dressing
Nakagami 2007 REMOISPAD(designed to reduce shear forceswith
a low friction outer layer and containing a ceramide
supplementation to improve the water-holding ca-
pacity of the skin. Ceramide is composed of sphin-
gosine and a fatty acid)
Qiuli 2010 Soft silicone, self adherent, bordered foam dressing
Smith 1985 Conotrane: consisting of a silicone cream, 20%
dimethicone 350, and a broad spectrum antiseptic
(0.05% hydrargaphen)
Torra i Bou 2005 Mepentol: a hyperoxygenated fatty acid compound
consisting of oleic acid, palmitic acid, stearic acid,
palmitoleic acid, linoleic acid, gamma linoleic acid,
arachidonic acid, and eicosenoic acid
Van Der Cammen 1987 Prevasore: consisting of hexyl nicotinate, zinc
stearate, isopropyl myristate, Dimethicone 350,
cetrimide and glycol
A P P E N D I C E S
Appendix 1. International NPUAP-EPUAP pressure ulcer classification system for ulcer grading
Category/Stage I: non-blanchable redness of intact skin
Intact skin with non-blanchable erythema of a localised area usually over a bony prominence. Discolouration of the skin, warmth,
oedema, hardness or pain may also be present. Darkly pigmented skin may not have visible blanching. Further description: the area
may be painful, firm, soft, warmer or cooler than adjacent tissue. Category/Stage I may be difficult to detect in individuals with dark
skin tones. May indicate ’at risk’ persons.
Category/Stage II: partial thickness skin loss or blister
Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without slough. May also present as
an intact or open/ruptured serum filled or sero-sanguinous filled blister. Further description: presents as a shiny or dry shallow ulcer
without slough or bruising. This category/stage should not be used to describe skin tears, tape burns, incontinence associated dermatitis,
maceration or excoriation.
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Category/Stage III: full thickness skin loss (fat visible)
Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle are not exposed. Some slough may be present.
May include undermining and tunnelling. Further description: the depth of a Category/Stage III pressure ulcer varies by anatomical
location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) subcutaneous tissue and Category/Stage III ulcers
can be shallow. In contrast, areas of significant adiposity can develop extremely deep Category/Stage III pressure ulcers. Bone/tendon
is not visible or directly palpable.
Category/Stage IV: full thickness tissue loss (muscle/bone visible)
Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present. Often include undermining and
tunnelling.Further description: the depth of a Category/Stage IV pressure ulcer varies by anatomical location. The bridge of the nose,
ear, occiput and malleolus do not have (adipose) subcutaneous tissue and these ulcers can be shallow. Category/Stage IV ulcers can
extend into muscle and/or supporting structures (e.g. fascia, tendon or joint capsule) making osteomyelitis or osteitis likely to occur.
Exposed bone/muscle is visible or directly palpable.
Appendix 2. Search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL
Ovid Medline
1 exp Biological Dressings/ (590)
2 exp Occlusive Dressings/ (1560)
3 exp Hydrogels/ (7950)
4 exp Alginates/ (4561)
5 dressing$.ti,ab. (7994)
6 (hydrocolloid$ or alginate$ or hydrogel$ or foam or bead or film or films or tulle or gauze or non-adherent or non adherent).ti,ab.
(72393)
7 exp Anti-Bacterial Agents/ (215334)
8 exp Administration, Topical/ (41359)
9 and/7-8 (2703)
10 (topical adj2 antibiotic$).ti,ab. (1112)
11 exp Antiinfective Agents, Local/ (83845)
12 exp Anti-Inflammatory Agents/ (180341)
13 exp Glucocorticoids/ (71762)
14 or/12-13 (191854)
15 8 and 14 (6251)
16 (topical adj2 (steroid$ or corticosteroid$ or glucocorticoid$)).ti,ab. (4415)
17 exp Estrogens/ (57995)
18 8 and 17 (1634)
19 (topical adj2 (oestrogen or estrogen)).ti,ab. (77)
20 exp Enzymes/ (1289849)
21 8 and 20 (2786)
22 (topical adj2 enzym$).ti,ab. (14)
23 exp Growth Substances/ (290263)
24 8 and 23 (1738)
25 (topical adj2 growth factor$).ti,ab. (55)
26 exp Collagen/ (52416)
27 8 and 26 (315)
28 (topical adj2 collagen).ti,ab. (17)
29 (topical adj2 silver).ti,ab. (62)
30 exp Honey/ (1486)
31 honey$.ti,ab. (7191)
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32 exp Ointments/ (3714)
33 (ointment$ or lotion$ or cream$).ti,ab. (11253)
34 (topical adj (agent$ or preparation$ or therap$ or treatment$)).ti,ab. (5368)
35 or/1-6,9-11,15-16,18-19,21-22,24-25,27-34 (198846)
36 exp Pressure Ulcer/ (5267)
37 (pressure adj (ulcer$ or sore$)).ti,ab. (4400)
38 (decubitus adj (ulcer$ or sore$)).ti,ab. (585)
39 (bedsore$ or (bed adj sore$)).ti,ab. (245)
40 or/36-39 (6597)
41 35 and 40 (679)
42 randomized controlled trial.pt. (243536)
43 controlled clinical trial.pt. (39760)
44 randomized.ab. (198232)
45 placebo.ab. (92274)
46 clinical trials as topic.sh. (80060)
47 randomly.ab. (136251)
48 trial.ti. (73632)
49 or/42-48 (549699)
50 Animals/ (2494493)
51 Humans/ (6922271)
52 50 not 51 (1627525)
53 49 not 52 (500327)
54 41 and 53 (151)
Ovid Embase
1 exp foam dressing/ (181)
2 exp gauze dressing/ (799)
3 exp hydrocolloid dressing/ (454)
4 exp hydrogel dressing/ (147)
5 exp Wound Dressing/ (6673)
6 exp Hydrogel/ (13683)
7 exp Calcium Alginate/ (1232)
8 dressing$.ti,ab. (11539)
9 (hydrocolloid$ or alginate$ or hydrogel$ or foam or bead or film or films or tulle or gauze or non-adherent or non adherent).ti,ab.
(110602)
10 exp Antibiotic Agent/ (543716)
11 exp Topical Drug Administration/ (14698)
12 and/10-11 (2182)
13 (topical adj2 antibiotic$).ti,ab. (1608)
14 exp Antiinfective Agent/ (1331673)
15 11 and 14 (5355)
16 exp Antiinflammatory Agent/ (743751)
17 exp Corticosteroid/ (401726)
18 exp Glucocorticoid/ (311297)
19 or/16-18 (830153)
20 11 and 19 (4840)
21 (topical adj2 (steroid$ or corticosteroid$ or glucocorticoid$)).ti,ab. (7159)
22 exp Estrogen/ (118910)
23 11 and 22 (207)
24 (topical adj2 (oestrogen or estrogen)).ti,ab. (149)
25 exp Enzymes/ (1821631)
26 11 and 25 (898)
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27 (topical adj2 enzym$).ti,ab. (19)
28 exp Growth Factor/ (318023)
29 11 and 28 (299)
30 (topical adj2 growth factor$).ti,ab. (72)
31 exp Collagen/ (96769)
32 11 and 31 (209)
33 (topical adj2 collagen).ti,ab. (21)
34 (topical adj2 silver).ti,ab. (90)
35 exp Honey/ (2696)
36 honey$.ti,ab. (10147)
37 exp Ointments/ (4759)
38 (ointment$ or lotion$ or cream$).ti,ab. (18505)
39 (topical adj (agent$ or preparation$ or therap$ or treatment*)).ti,ab. (8287)
40 or/1-9,12-13,15,20-21,23-24,26-27,29-30,32-39 (173972)
41 exp Decubitus/ (9199)
42 (pressure adj (ulcer$ or sore$)).ti,ab. (5687)
43 (decubitus adj (ulcer$ or sore$)).ti,ab. (781)
44 (bedsore$ or (bed adj sore$)).ti,ab. (415)
45 or/41-44 (10385)
46 40 and 45 (1126)
47 exp Clinical trial/ (793074)
48 Randomized controlled trial/ (286529)
49 Randomization/ (50655)
50 Single blind procedure/ (15585)
51 Double blind procedure/ (85986)
52 Crossover procedure/ (31907)
53 Placebo/ (165507)
54 Randomi?ed controlled trial$.tw. (80377)
55 RCT.tw. (10556)
56 Random allocation.tw. (910)
57 Randomly allocated.tw. (14266)
58 Allocated randomly.tw. (1214)
59 (allocated adj2 random).tw. (264)
60 Single blind$.tw. (9677)
61 Double blind$.tw. (90376)
62 ((treble or triple) adj blind$).tw. (239)
63 Placebo$.tw. (137423)
64 Prospective study/ (200692)
65 or/47-64 (1088348)
66 Case study/ (15964)
67 Case report.tw. (167009)
68 Abstract report/ or letter/ (511635)
69 or/66-68 (690338)
70 65 not 69 (1060158)
71 animal/ (725145)
72 human/ (8645166)
73 71 not 72 (484830)
74 70 not 73 (1037853)
75 46 and 74 (309)
EBSCO CINAHL
S39 S33 and S38
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S38 S34 or S35 or S36 or S37
S37 TI decubitus or AB decubitus
S36 TI ( bed sore* or bedsore* ) or AB ( bed sore* or bedsore* )
S35 TI ( pressure ulcer* or pressure sore* ) or AB ( pressure ulcer* or pressure sore* )
S34 (MH ”Pressure Ulcer“)
S33 S1 or S2 or S3 or S6 or S7 or S8 or S9 or S10 or S12 or S13 or S15 or S16 or S18 or S19 or S21 or S22 or S26 or S27 or S28 or
S29 or S30 or S31 or S32
S32 TI ( topical agent* or topical preparation* or topical therap* or topical treatment*) or AB ( topical agent* or topical preparation*
or topical therap* or topical treatment*)
S31 TI ( ointment* or lotion* or cream* ) or AB ( ointment* or lotion* or cream* )
S30 (MH ”Ointments“)
S29 TI honey* or AB honey*
S28 (MH ”Honey“)
S27 TI topical* N2 silver* or AB topical* N2 silver*
S26 S5 and S25
S25 S23 or S24
S24 (MH ”Silver Sulfadiazine“)
S23 (MH ”Silver“)
S22 TI collagen* or AB collagen*
S21 S5 and S20
S20 (MH ”Collagen“)
S19 TI topical* N2 growth factor* or AB topical* N2 growth factor*
S18 (S5 and S17)
S17 (MH ”Growth Substances+“)
S16 TI topical* N2 enzyme* or AB topical* N2 enzyme*
S15 S5 and S14
S14 (MH ”Enzymes+“)
S13 TI ( topical* N2 oestrogen* or topical* N2 estrogen* ) or AB ( topical* N2 oestrogen* or topical* N2 estrogen* )
S12 S5 and S11
S11 (MH ”Estrogens+“)
S10 TI ( topical* N2 steroid* or topical* N2 corticosteroid* or topical* N2 glucocorticoid* ) or AB ( topical* N2 steroid* or topical*
N2 corticosteroid* or topical* N2 glucocorticoid* )
S9 (MH ”Antiinflammatory Agents, Topical+“)
S8 (MH ”Antiinfective Agents, Local+“)
S7 TI topical* N2 antibiotic* or AB topical* N2 antibiotic*
S6 S4 and S5
S5 MH ”Administration, Topical+“)
S4 (MH ”Antibiotics+“)
S3 TI ( dressing* or pad or pads or gauze or tulle or film or bead or foam* or non-adherent or non adherent or hydrocolloid* or
alginat* or hydrogel* ) or AB (dressing* or pad or pads or gauze or tulle or film or bead or foam* or non-adherent or non adherent or
hydrocolloid* or alginat* or hydrogel* )
S2 (MH ”Alginates“)
S1 (MH ”Bandages and Dressings+“)
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Appendix 3. Risk of bias criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of randomnumbers); assignment envelopes were usedwithout appropriate
safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
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3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
High risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Any one of the following:
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
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• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following:
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
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High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• had extreme baseline imbalance; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
WH A T ’ S N E W
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